SRS Capital Advisors Inc. Sells 874 Shares of Bruker Co. (NASDAQ:BRKR)

SRS Capital Advisors Inc. trimmed its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 35.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,573 shares of the medical research company’s stock after selling 874 shares during the period. SRS Capital Advisors Inc.’s holdings in Bruker were worth $92,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. True Wealth Design LLC grew its holdings in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after acquiring an additional 510 shares during the last quarter. Eagle Bay Advisors LLC grew its position in shares of Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after buying an additional 674 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after buying an additional 248 shares during the period. GAMMA Investing LLC increased its stake in shares of Bruker by 47.5% during the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after buying an additional 412 shares during the period. Finally, Capital Performance Advisors LLP bought a new position in shares of Bruker during the third quarter valued at approximately $77,000. 79.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BRKR. Barclays cut their target price on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a research report on Thursday, December 5th. Stifel Nicolaus decreased their target price on Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a research report on Friday, February 14th. UBS Group started coverage on Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target on the stock. Finally, Bank of America upped their price target on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Bruker Stock Up 2.8 %

Shares of NASDAQ BRKR opened at $48.20 on Friday. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. Bruker Co. has a 12-month low of $45.29 and a 12-month high of $94.86. The firm’s 50-day moving average price is $55.37 and its 200-day moving average price is $59.28. The stock has a market capitalization of $7.31 billion, a price-to-earnings ratio of 63.42, a P/E/G ratio of 2.16 and a beta of 1.16.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, equities research analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.41%. The ex-dividend date is Monday, March 17th. Bruker’s dividend payout ratio is presently 26.32%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.